Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.8%

2 terminated/withdrawn out of 237 trials

Success Rate

99.1%

+12.6% vs industry average

Late-Stage Pipeline

10%

23 trials in Phase 3/4

Results Transparency

14%

31 of 227 completed trials have results

Key Signals

1 recruiting31 with results

Enrollment Performance

Analytics

Phase 1
190(81.5%)
Phase 2
20(8.6%)
Phase 3
17(7.3%)
Phase 4
6(2.6%)
233Total
Phase 1(190)
Phase 2(20)
Phase 3(17)
Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (237)

Showing 20 of 237 trials
NCT07475572Phase 1Not Yet Recruiting

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Role: collaborator

NCT00404989Recruiting

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

Role: collaborator

NCT05296629Phase 3Completed

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

Role: collaborator

NCT05343455Phase 3Completed

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

Role: collaborator

NCT01871727Phase 3Completed

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Role: collaborator

NCT03976102Phase 3Completed

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

Role: lead

NCT04885829Phase 1Completed

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Role: collaborator

NCT04268771Phase 3Completed

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Role: lead

NCT06126042Phase 1Unknown

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

Role: lead

NCT05597462Phase 1Completed

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Role: collaborator

NCT05452785Phase 1Completed

A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects

Role: collaborator

NCT03009019Phase 3Completed

Efficacy, Tolerability, and Safety of DFN-15

Role: collaborator

NCT02173301Phase 2Completed

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Role: lead

NCT03421197Phase 2Completed

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Role: lead

NCT04529499Phase 3Terminated

Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

Role: lead

NCT02061813Phase 1Completed

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

Role: lead

NCT01518699Phase 1Completed

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Role: lead

NCT04640233Phase 2Unknown

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Role: lead

NCT02097485Phase 2Completed

Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Role: lead

NCT03292640Phase 3Completed

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

Role: lead